Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abnormal plasminogen Maywood I.

K C Robbins1, I G Boreisha, J E Godwin

  • 1Department of Medicine, Northwestern University Medical School, Chicago, IL 60611.

Thrombosis and Haemostasis
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Maywood I is a dysfunctional plasminogen variant identified in a patient with reduced plasma activity. This plasminogen shows significantly impaired activation by various plasminogen activators, indicating a novel genetic defect.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Leukemia·2012
Same author

Successful use of sodium ferric gluconate in sucrose in a patient with multiple drug allergies.

Nephrology nursing journal : journal of the American Nephrology Nurses' Association·2006
Same author

Diffuse large-cell lymphomas: a review of therapy.

Clinical lymphoma·2002
Same author

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

Transfusion·2001
Same author

Iron overload in the erythropoietin era.

Nephrology nursing journal : journal of the American Nephrology Nurses' Association·2000
Same author

A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation.

The Annals of pharmacotherapy·2000
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Plasminogen is a crucial protein in the fibrinolytic system, responsible for breaking down blood clots.
  • Dysfunctional plasminogen variants can lead to impaired fibrinolysis and potentially thrombotic disorders.
  • Understanding the molecular basis of these variants is essential for diagnosing and managing related hemostatic abnormalities.